A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer

Autor: Kamaraju, Sailaja ^{1, ⁎}, Fowler, Amy ^{#, 2}, Tarima, Sergey ³, Chaudhary, Lubna N. ¹, Burkard, Mark E. ⁴, Giever, Thomas ⁵, Cheng, Yee C. ¹, Parkes, Amanda ⁶, Lange, Carol A. ⁷, Pipp-Dahm, Michele ⁸, Hegeman, Robert ⁹, Siddiqui, Nauman ⁹, Stella, Amy ¹⁰, Rajguru, Saurabh ¹¹, Twaroski, Kyleigh ¹², Zurbriggen, Luke ¹³, Jorns, Julie M. ¹⁴, Rui, Hallgeir ¹⁵, Keigley, Quinton J. ¹⁶, Perlman, Scott B. ¹⁷, Salem, Kelley ¹⁸, Bradshaw, Tyler J. ¹⁹, Sahmoud, Tarek ²⁰, Wisinski, Kari ²¹

Publikováno v: In Clinical Breast Cancer November 2024

Does Progesterone Receptor Matter in the Risk of Recurrence for Patients With Ductal Carcinoma in Situ?

Autor: Chaudhary LN; Medical College of Wisconsin, Division of Hematology and Oncology, Milwaukee, Wisconsin, lchaudhary@mcw.edu., Jawa Z; Medical College of Wisconsin, Division of Hematology and Oncology, Milwaukee, Wisconsin., Hanif A; Medical College of Wisconsin, Department of Internal Medicine, Milwaukee, Wisconsin., Szabo A; Medical College of Wisconsin, Division of Biostatistics, Milwaukee, Wisconsin., Kamaraju S; Medical College of Wisconsin, Division of Hematology and Oncology, Milwaukee, Wisconsin., Cheng YC; Medical College of Wisconsin, Division of Hematology and Oncology, Milwaukee, Wisconsin., Chitambar CR; Medical College of Wisconsin, Division of Hematology and Oncology, Milwaukee, Wisconsin.

Publikováno v: WMJ : official publication of the State Medical Society of Wisconsin [WMJ] 2018 Jun; Vol. 117 (2), pp. 62-67.